A working method for ranking a pharma product page, built from what actually moves the needle across the projects we have run, not a generic SEO checklist with a compliance disclaimer bolted on.
Most SEO advice is written for consumer brands and applied to pharma sites as if the difference were cosmetic. It is not: regulatory review, multi-affiliate site structures, and low consent rates change the order operations should happen in, not just the tactics inside them. This playbook lays out that order, from defining the regulatory boundary before researching a single keyword, through fixing the technical foundation, building a content cadence your medical reviewers can actually sustain, separating branded from unbranded content correctly, measuring honestly under real consent limits, and preparing content for the AI answer engines that increasingly summarise rather than list. Each stage exists because skipping it, or doing it out of order, is where we see most pharma SEO programmes actually break down.
Every generic SEO process starts with keyword research: pull search volume, rank by opportunity, build a content plan. To rank a pharma product page, that order is backwards. A term with excellent volume and difficulty is worthless if it implies an unapproved use, and a product page built around it gets rejected wholesale at the first medical review, wasting the research entirely.
The working order is the opposite: establish the approved indication and claims for that specific product first, then research keywords within that boundary. This produces a smaller keyword set for the product page than a generic tool would suggest, and that is the correct outcome, not a limitation to work around later.
In practice, this means the first working document for a product page is not a keyword list but the current set of approved indications and claims, sourced directly from regulatory and medical affairs before a single search term is pulled. Keyword research then runs as a filter against that document rather than ahead of it: a term only gets shortlisted for the product page if it can be addressed without straying past an approved claim.
The highest-leverage work on most pharma product pages we audit is not content, it is technical: indexability gaps, multilingual targeting declared incorrectly or not at all, and structural issues that block a crawler from reaching a product page that already has decent content on it. See hreflang for pharma websites for the single most common and highest-impact fix we make on multi-market product pages.
A product page written against a technically broken foundation performs worse than a mediocre product page on a technically sound one. This ordering matters more for a product page than for most other content, because the same product usually has one page per market, and technical debt compounds across every market simultaneously.
The pattern we see most often is a multi-affiliate estate where each country built its own version of the same product page independently, each with its own hreflang implementation, without anyone auditing the whole set together. The result is not a missing tag here or there but product pages that quietly compete against each other and against the global domain for the same searches, splitting authority that should have reinforced a single ranking page.
Fixing this is a one-time technical exercise, not an ongoing content task, which is exactly why it belongs before any work on the product page’s copy starts rather than running alongside it: correcting hreflang and canonical signals across the estate does not depend on anything a writer produces.
A product page is not written once and left. Indications get added, safety information updates, claims get revised — and each of those changes needs the same medical review the original page went through. Treating the product page as finished after launch is where the ranking a product page has built up quietly erodes: an outdated claim left live is both a compliance risk and, eventually, a reason the page stops matching what the approved label actually says.
Any change to the product page should flag the evidence a new or revised claim will need before drafting starts, so medical review is not the first point at which a citation gets checked. Catching an unsupported claim at the brief stage costs a rewrite of a sentence; catching the same claim at review, after the product page has already been redrafted around it, costs a rewrite of the argument the whole update was built on.
A brief that does this consistently tends to cover the same handful of points every time:
Disease-awareness content frequently has more room to rank for high-intent condition searches than a branded product page ever will, precisely because it is not tied to promoting a specific treatment. Trying to make the product page also carry that condition-education search intent is a common and costly strategic mistake — it dilutes the page and puts unbranded-style content in a place regulators scrutinise most closely.
See disease awareness website for how that content is structured and kept genuinely separate from the product page, which matters for both regulatory and ranking reasons.
That separation is not only editorial, it has to be structural to hold up: unbranded content built as a genuinely separate property, often on its own domain or subdomain with no shared navigation or branding, protects both the regulatory boundary and the product page’s own ability to rank for the narrower, branded searches it is actually meant to capture.
Health-related sites see lower consent rates than general e-commerce, which means a meaningful share of a product page’s organic traffic is simply not trackable at an individual level. A measurement plan that implies complete visibility into the product page’s performance either overstates what the data shows or quietly assumes consent behaviour that is not present.
In practice, this means reporting a stated coverage rate alongside every organic traffic number for the product page — the share of sessions where consent actually allows tracking — rather than presenting the trackable subset as if it were the whole picture. A smaller, clearly qualified number is more useful than a larger figure that cannot be substantiated.
Structuring the product page’s content as clear, extractable factual statements, with structured data marking up key facts, increasingly determines whether an AI answer engine cites that product page or a competitor’s when a prospect asks a summarised question rather than searching a ranked list. See AI search visibility for how this connects to and extends the technical SEO work already done on the page.
Concretely, this means moving technical specification data out of prose and PDFs and into structured, semantic tables an answer engine can parse, stating the approved indication and mechanism-of-action content as plain factual statements rather than adjective-heavy marketing copy, and adding schema markup for the product, the organisation, and any FAQ content on the page, per Google’s own structured data documentation.
Yes — the biggest gains typically come from fixing indexability and hreflang, not from writing more content, since technical debt compounds across every market a product page exists in. Competitors in this category often under-invest in the technical foundation specifically, which is why correcting it tends to outperform content investment on its own. See does SEO work for pharma for the fuller case.
Correcting hreflang and canonical targeting across a product’s per-market pages, since a multi-affiliate estate where each country built its own version independently is the most common source of pages quietly competing against each other and against the global domain. This is a one-time technical fix rather than an ongoing content task, and it should be resolved before any copy work starts. See hreflang for pharma websites for the mechanics.
The sequencing reverses the usual order: the approved indication and claims are established before any keyword research runs, rather than after, so a term never gets shortlisted if it strays past what medical affairs has approved. Technical foundation work then comes before content, and condition-education content stays off the product page entirely rather than blended into it, since that dilutes the page and invites closer regulatory scrutiny.
Report a stated consent-coverage rate alongside every organic traffic figure, rather than presenting the trackable subset of sessions as the whole picture. Health-related sites see lower consent rates than general e-commerce, so a meaningful share of a product page’s traffic is never individually trackable, and a measurement plan that implies full visibility overstates what the data shows. A smaller, clearly qualified number is more useful than an inflated one.
Tell us about your current product page and we will tell you where this would start.